Skip to main content
Oligonucleotide Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, Germany, Japan - Size and Forecast 2024-2028

Oligonucleotide Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, Germany, Japan - Size and Forecast 2024-2028

Published: Apr 2024 169 Pages SKU: IRTNTR41378

Market Overview at a Glance

$13.44 B
Market Opportunity
19.87%
CAGR
17.98
YoY growth 2023-2024(%)

Oligonucleotide Therapeutics Market Size 2024-2028

The oligonucleotide therapeutics market size is forecast to increase by USD 13.44 billion at a CAGR of 19.87% between 2023 and 2028.

  • The market is experiencing significant growth due to several key trends. The increasing incidence of cancer and the subsequent need for novel diagnostic tools are driving market demand. Advancements in DNA sequencing technology and the adoption of microfluidic techniques are also contributing to market growth. However, inherent issues associated with oligonucleotide therapies, such as high production costs and potential off-target effects, pose challenges to market expansion. Despite these challenges, the market is expected to continue growing due to the potential of these therapies to treat a wide range of genetic disorders and diseases. The market's future looks promising, with ongoing research and development efforts aimed at overcoming the challenges and improving the efficacy and safety of oligonucleotide therapies.

    • What will be the Size of the Oligonucleotide Therapeutics Market During the Forecast Period?

    Oligonucleotide Therapeutics Market Size

     Request Free Sample

  • The market encompasses a range of innovative technologies, including antisense, ribozymes, aptamers, CPG/immunostimulatory oligonucleotides, RNAi, and miRNA, which offer significant potential in addressing various genetic disorders and diseases. These therapeutics function by selectively targeting specific genes, RNA, or biological processes, such as gene expression and RNA targets, to modify or inhibit their activity. Key applications include infectious diseases, oncology, and detecting minor antibodies. Healthcare reforms and increasing healthcare expenditure have fueled the growth of this market, as precision medicine gains traction and the demand for personalized treatment solutions rises. Antisense oligonucleotides, miRNA, and RNAi are particularly noteworthy for their ability to modulate gene expression and provide therapeutic benefits in cancer and other disorders.
  • Biomedical science continues to advance, offering new opportunities for the development of these nucleotide-based therapeutics.

    • How is this Oligonucleotide Therapeutics Industry segmented and which is the largest segment?

    The oligonucleotide therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

    • Type
      • Antisense oligonucleotides
      • RNA interference
      • Aptamers and others
    • Application
      • Neurological
      • Cancer
      • Infectious diseases and others
    • Geography
      • North America
        • Canada
        • US
      • Europe
        • Germany
        • UK
      • Asia
        • Japan
      • Rest of World (ROW)

      By Type Insights

      • The antisense oligonucleotides segment is estimated to witness significant growth during the forecast period.

      Oligonucleotide therapeutics, which include antisense RNA, RNAi, miRNA, aptamers, CpG/immunostimulatory, and RNA vaccines, have emerged as promising therapeutic agents for treating various diseases, such as genetic disorders, cancer, neurodegenerative disorders, cardiovascular diseases, and kidney diseases. The advancements in biomedical science and pharmaceutical research, particularly In the areas of gene expression and RNA targets, have fueled the growth of this market. The shift towards precision medicine and personalized therapies has further increased the demand for oligonucleotide therapeutics, as they offer the potential for targeted therapies with minimal off-target effects. The expanding pipeline of ASO-based drugs in clinical development, including those for treating ATTR, hepatic VOD, and cancer, is driving the demand for oligonucleotide therapeutics services.

      The healthcare reforms and increasing healthcare expenditure are also contributing to the growth of this market. Oligonucleotide therapeutics offer a new approach to treating diseases by targeting specific genes and biological processes, making them an attractive option for pharmaceutical firms and researchers In the biotechnology industry.

      Oligonucleotide Therapeutics Market Size

      Get a glance at the  Oligonucleotide Therapeutics Industry report of share of various segments Request Free Sample

      The Antisense oligonucleotides segment was valued at USD 1.89 billion in 2018 and showed a gradual increase during the forecast period.

      Regional Analysis

      • North America is estimated to contribute 39% to the growth of the global market during the forecast period.

      Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

      Oligonucleotide Therapeutics Market Share by Geography

      For more insights on the market share of various regions, Request Free Sample

      The North American market for oligonucleotide therapeutics is expected to lead due to advanced healthcare systems In the US and Canada, accommodating a significant disease burden. The region's dominance is primarily driven by substantial investments in healthcare research and testing, with key contributors being the National Institute of Health and other funding agencies In the US. Oligonucleotide therapeutics, including Antisense RNA, RNAi treatments, miRNA, CpG/Immunostimulatory, and RNA vaccines, are revolutionizing biomedical science by targeting specific genes and biological processes related to various disorders such as Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, and Kidney Diseases. These therapies offer precision medicine approaches to treat disorders at their root cause.

      Key applications include detecting minor antibodies and addressing rare genetic disorders like ATTR and Hepatic VOD. Pharmaceutical firms are increasingly investing in RNA-based therapeutic techniques, such as CRISPR-Cas9, to expand their portfolios and cater to the growing demand.

      Market Dynamics

      Our  researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

      What are the key market drivers leading to the rise In the adoption of Oligonucleotide Therapeutics Industry?

      Increasing incidence of cancer boosts demand for novel diagnostics is the key driver of the market.

    • The market encompasses various RNA-based therapeutic techniques, including Antisense RNA, RNAi treatments, miRNA, and CRISPR-Cas9, to address disorders in Genes related to Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, and Kidney Diseases. These techniques detect minor antibodies and target specific biological processes, providing precision medicine solutions. The increasing prevalence of chronic diseases, such as cancer, cardiovascular diseases, and neurodegenerative disorders, necessitates the development of novel therapeutics. For instance, Antisense oligonucleotides target specific mRNA to inhibit gene expression, while RNAi treatments silence genes by degrading their mRNA. MiRNA acts as a post-transcriptional regulator, influencing gene expression. Pharmaceutical firms are investing heavily in RNA-based therapeutic research, including RNA vaccines and CpG/Immunostimulatory RNA.
    • For example, Biogen's Spinraza, an antisense oligonucleotide, is used to treat Spinal Muscular Atrophy (SMA). MiRNA-based therapies are being explored for the treatment of ATTRTACHR (ATTR amyloidosis) and Hepatic Veno-Occlusive Disease (HVOD). In the field of Biomedical science, RNA-based therapeutics offer significant potential for treating various disorders. As healthcare reforms and expenditure continue to rise, the demand for effective medications to address these disorders is increasing. The market is expected to grow substantially In the coming years. Neuromuscular diseases, such as SMA, Duchenne Muscular Dystrophy, and Huntington's Disease, are potential applications of Antisense RNA and RNAi treatments. In oncology, RNA-based therapeutics are being explored for cancer treatment, including RNA vaccines and miRNA-based therapies.
    • In neurodegenerative disorders, RNA-based therapeutics hold promise for treating Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease. In summary, the growing incidence of chronic diseases, the potential of RNA-based therapeutics to address various disorders, and the increasing healthcare expenditure are driving the growth of the market. Pharmaceutical research and biotechnology are focusing on developing RNA-based therapeutics for various applications, including cancer, neurodegenerative disorders, and cardiovascular diseases.

      • What are the market trends shaping the Oligonucleotide Therapeutics Industry?

      Advances in DNA sequencing increasing adoption of microfluidic techniques is the upcoming market trend.

    • Oligonucleotide therapeutics, a segment of RNA-based medicines, encompasses various techniques such as Antisense RNA, Ribozymes, Aptamers, miRNA, CpG/Immunostimulatory RNA, RNAi, and CRISPR-Cas9. These therapeutic approaches target specific genes and biological processes implicated in various disorders, including Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, and Neuromuscular diseases. The advancements in Biomedical science and Pharmaceutical research have led to the development of RNA-based therapeutic techniques like Antisense oligonucleotides, miRNA, and RNA vaccines. These treatments have the potential to detect minor antibodies and modify gene expression by targeting RNA, offering a promising alternative to traditional medications. Healthcare reforms and increasing healthcare expenditure have fueled the growth of this market.
    • The global market for Oligonucleotide therapeutics is expected to witness significant expansion due to the increasing prevalence of disorders like ATTR, Hepatic VOD, and Cancer. The development of new technologies, such as microRNA (miRNA) and CRISPR-Cas9, is expected to further drive market growth. Biotechnology firms are investing heavily in Pharmaceutical research to develop novel Oligonucleotide therapeutics for various indications. Genetic testing and RNAi treatments are also gaining popularity due to their potential to treat disorders at their root cause. In conclusion, the market is poised for significant growth due to the increasing prevalence of various disorders and the development of advanced RNA-based therapeutic techniques.
    • These treatments offer a promising alternative to traditional medications and have the potential to revolutionize the field of Precision medicine.

      • What challenges does the Oligonucleotide Therapeutics Industry face during its growth?

      Inherent issues associated with oligonucleotide therapies is a key challenge affecting the industry growth.

    • Oligonucleotide therapy, which encompasses Antisense RNA, Ribozymes, Aptamers, miRNA, CpG/Immunostimulatory RNA, RNAi, and RNA vaccines, holds significant potential in advancing biomedical research. Applications of these nucleotide-based medications are predominantly in academic research, with promising prospects in publications for various disorders such as Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, and Kidney Diseases. However, the market's growth is hindered by the lack of transitional research addressing real-world medical and scientific challenges. Single-cell mRNA is a potential therapeutic agent, but the translation from academic research to industry application remains unexplored. The delivery of Antisense Oligonucleotides (ASOs) and RNAi molecules into the targeted cell, tissue, or organ is a significant challenge, as self-administration is not feasible.
    • Gene disorders, such as ATTR and Hepatic VOD, may benefit from these RNA-based therapeutic techniques. Pharmaceutical firms are investing in Pharmaceutical research and Biotechnology to overcome these challenges and bring these innovative treatments to market. Gene expression and RNA targets play a crucial role in biological processes, and the advancements in RNA-based therapeutic techniques, including CRISPR-Cas9, are revolutionizing Precision medicine. The healthcare reforms and increased healthcare expenditure In the US further emphasize the need for novel medications to address various Disorders and Genes.

      • Exclusive Customer Landscape

      The oligonucleotide therapeutics market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the oligonucleotide therapeutics market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

      Oligonucleotide Therapeutics Market Share by Geography

       Customer Landscape

      Key Companies & Market Insights

      Companies are implementing various strategies, such as strategic alliances, oligonucleotide therapeutics market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence In the industry.

      Agilent Technologies Inc. - The Agilent synthetic oligonucleotides platform provides access to a range of oligonucleotide therapeutics, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs). These therapeutics leverage the specificity of nucleic acid sequences to modulate gene expression or RNA function, offering potential treatments for various diseases. Agilent's platform ensures the highest quality and accuracy in oligonucleotide synthesis, enabling effective digital analysis for therapeutic applications. By harnessing the power of oligonucleotide technology, the company is at the forefront of advancing innovative therapeutic solutions.

      The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

      • Agilent Technologies Inc.
      • Alnylam Pharmaceuticals Inc.
      • Biogen Inc.
      • CSL Ltd.
      • GlaxoSmithKline Plc
      • Ionis Pharmaceuticals Inc.
      • Maravai LifeSciences Holdings Inc.
      • Merck KGaA
      • Nippon Shinyaku Co. Ltd.
      • Novartis AG
      • Pfizer Inc.
      • Sarepta Therapeutics Inc.
      • Thermo Fisher Scientific Inc.

      Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

      Research Analyst Overview

      Oligonucleotide therapeutics represent a burgeoning field In the realm of pharmaceutical research, offering innovative solutions for addressing various disorders and diseases. These therapeutics, which include antisense RNA, RNAi treatments, aptamers, and RNA-based vaccines, harness the power of nucleotides to manipulate gene expression and biological processes. Antisense RNA and RNAi treatments represent two primary classes of oligonucleotide therapeutics. Antisense RNA functions by binding to specific mRNA sequences, thereby inhibiting their translation into proteins. RNAi treatments, on the other hand, utilize small RNA molecules to degrade specific mRNAs. Both approaches offer potential for treating a range of disorders, including infectious diseases, neurodegenerative disorders, oncology, cardiovascular diseases, and kidney diseases.

      Another class of oligonucleotide therapeutics includes aptamers, which are short, single-stranded RNA or DNA molecules that can bind to specific targets with high affinity and specificity. Aptamers have shown promise in detecting minor antibodies and can be used as therapeutic agents in various applications. MicroRNAs (miRNAs) represent another category of RNA-based therapeutic techniques. MiRNAs are small non-coding RNAs that regulate gene expression by binding to specific mRNAs. MiRNAs have been implicated in various biological processes and offer potential for treating a range of disorders, including cancer, neurological diseases, and cardiovascular diseases. The development of oligonucleotide therapeutics is driven by advancements in biomedical science and biotechnology.

      Pharmaceutical firms are investing heavily in research and development of these therapeutics, driven by the potential for precision medicine and the ability to target specific genetic disorders. The application of CRISPR-Cas9 technology, a revolutionary gene-editing tool, has further expanded the potential of oligonucleotide therapeutics. This technology allows for precise modification of DNA sequences, offering potential for treating a wide range of genetic disorders. Despite the promising potential of oligonucleotide therapeutics, there are challenges to their development and commercialization. These challenges include the high cost of production, the need for specific delivery systems, and the potential for off-target effects.

      In conclusion, oligonucleotide therapeutics represent a promising field in pharmaceutical research, offering innovative solutions for addressing various disorders and diseases. These therapeutics, which include antisense RNA, RNAi treatments, aptamers, and RNA-based vaccines, harness the power of nucleotides to manipulate gene expression and biological processes. The development of these therapeutics is driven by advancements in biomedical science and biotechnology, and offers potential for precision medicine and the treatment of a wide range of disorders. However, challenges remain, including the high cost of production, the need for specific delivery systems, and the potential for off-target effects.

      Market Scope

      Report Coverage

      Details

      Page number

      169

      Base year

      2023

      Historic period

      		 2018-2022

      Forecast period

      2024-2028

      Growth momentum & CAGR

      Accelerate at a CAGR of 19.87%

      Market growth 2024-2028

      USD 13443.7 million

      Market structure

      Fragmented

      YoY growth 2023-2024(%)

      17.98

      Key countries

      US, Canada, UK, Germany, and Japan

      Competitive landscape

      Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

      Request Free Sample

      What are the Key Data Covered in this Oligonucleotide Therapeutics Market Research and Growth Report?

      • CAGR of the Oligonucleotide Therapeutics industry during the forecast period
      • Detailed information on factors that will drive the growth and forecasting between 2024 and 2028
      • Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
      • Accurate predictions about upcoming growth and trends and changes in consumer behaviour
      • Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
      • Thorough analysis of the market’s competitive landscape and detailed information about companies
      • Comprehensive analysis of factors that will challenge the oligonucleotide therapeutics market growth of industry companies

      We can help! Our analysts can customize this oligonucleotide therapeutics market research report to meet your requirements.

      Get in touch

       

      Table of Contents not available.

      Research Methodology

      Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

      INFORMATION SOURCES

      Primary sources

      • Manufacturers and suppliers
      • Channel partners
      • Industry experts
      • Strategic decision makers

      Secondary sources

      • Industry journals and periodicals
      • Government data
      • Financial reports of key industry players
      • Historical data
      • Press releases

      DATA ANALYSIS

      Data Synthesis

      • Collation of data
      • Estimation of key figures
      • Analysis of derived insights

      Data Validation

      • Triangulation with data models
      • Reference against proprietary databases
      • Corroboration with industry experts

      REPORT WRITING

      Qualitative

      • Market drivers
      • Market challenges
      • Market trends
      • Five forces analysis

      Quantitative

      • Market size and forecast
      • Market segmentation
      • Geographical insights
      • Competitive landscape

      Interested in this report?

      Get your sample now to see our research methodology and insights!

      Download Now

      Frequently Asked Questions

      Oligonucleotide Therapeutics market growth will increase by $ 13443.7 mn during 2024-2028.

      The Oligonucleotide Therapeutics market is expected to grow at a CAGR of 19.87% during 2024-2028.

      Oligonucleotide Therapeutics market is segmented by Type( Antisense oligonucleotides, RNA interference, Aptamers and others) Application( Neurological, Cancer, Infectious diseases and others)

      Agilent Technologies Inc., Alnylam Pharmaceuticals Inc., Biogen Inc., CSL Ltd., GlaxoSmithKline Plc, Ionis Pharmaceuticals Inc., Maravai LifeSciences Holdings Inc., Merck KGaA, Nippon Shinyaku Co. Ltd., Novartis AG, Pfizer Inc., Sarepta Therapeutics Inc., Thermo Fisher Scientific Inc. are a few of the key vendors in the Oligonucleotide Therapeutics market.

      North America will register the highest growth rate of 39% among the other regions. Therefore, the Oligonucleotide Therapeutics market in North America is expected to garner significant business opportunities for the vendors during the forecast period.

      US, Canada, UK, Germany, Japan

      • Increasing incidence of cancer boosts demand for novel diagnosticsThe prevalence of chronic diseases such as cancer is the driving factor this market.
      • CVD is the driving factor this market.
      • diabetes is the driving factor this market.
      • and autoimmune diseases is growing due to factors such as the increase in pollution and the adoption of a sedentary lifestyle. Globally is the driving factor this market.
      • cancer leads to high annual rates of mortality. The growing incidence of chronic diseases has increased the need for novel therapeutics. New cancer cases in Europe rose by 2.3 % compared to 2020 and reached 2.74 million in 2022. Similarly is the driving factor this market.
      • cancer deaths in Europe went up by 2.4% in the same period is the driving factor this market.
      • according to the European Union. The growing incidence of cancer has increased the need for novel therapeutics. To accurately detect cancer cells is the driving factor this market.
      • diagnostic tests primarily rely on antibody-antigen binding assays is the driving factor this market.
      • which may have a few limitations is the driving factor this market.
      • such as the inability to detect minor antibodies. Oligonucleotide therapeutics provide a new class of nucleic acid probes known as aptamers is the driving factor this market.
      • which are better probes than monoclonal antibodies (mAbs). Aptamers are short single-stranded DNA (ssDNA) or RNA oligonucleotides is the driving factor this market.
      • which recognize the target with high specificity and sensitivity. Unlike mAbs is the driving factor this market.
      • which are stable only at low temperatures is the driving factor this market.
      • aptamers are stable at ambient temperatures. Aptamers can be produced in vitro and is the driving factor this market.
      • hence is the driving factor this market.
      • are more cost-effective than monoclonal antibodies (mAbs) is the driving factor this market.
      • which require animal hosts. Thus is the driving factor this market.
      • oligonucleotides can have high selectivity is the driving factor this market.
      • affinity is the driving factor this market.
      • and stability is the driving factor this market.
      • and they can be used as molecular probes in bioanalysis and biomedicine. Hence is the driving factor this market.
      • the rising prevalence of chronic and infectious diseases increases the demand for novel therapies is the driving factor this market.
      • thus driving the global oligonucleotide therapeutics market during the forecast period. is the driving factor this market.

      The Oligonucleotide Therapeutics market vendors should focus on grabbing business opportunities from the Antisense oligonucleotides segment as it accounted for the largest market share in the base year.